An Exploratory, Observational, Multicentre Study to Investigate the Impact of the Presence of JAK2 (V617F) Mutation on Treatment Response in Patients With Essential Thrombocythaemia Treated With XAGRID (Anagrelide Hydrochloride).

Trial Profile

An Exploratory, Observational, Multicentre Study to Investigate the Impact of the Presence of JAK2 (V617F) Mutation on Treatment Response in Patients With Essential Thrombocythaemia Treated With XAGRID (Anagrelide Hydrochloride).

Completed
Phase of Trial: Phase IV

Latest Information Update: 30 Sep 2014

At a glance

  • Drugs Anagrelide (Primary)
  • Indications Embolism and thrombosis; Essential thrombocythaemia
  • Focus Pharmacogenomic; Therapeutic Use
  • Acronyms EMIX
  • Sponsors Shire
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 01 Oct 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 14 Feb 2013 Planned End Date changed from 1 Jan 2014 to 1 Sep 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top